Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24526268)

1.

Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.

Shah DR, Dholakia S, Shah RR.

Drug Saf. 2014 Mar;37(3):135-49. doi: 10.1007/s40264-014-0139-x. Review.

PMID:
24526268
2.

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 Jul;36(7):491-503. doi: 10.1007/s40264-013-0048-4. Review.

PMID:
23620168
3.

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5. Review.

PMID:
23620167
4.

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Shah DR, Shah RR, Morganroth J.

Drug Saf. 2013 Jun;36(6):413-26. doi: 10.1007/s40264-013-0050-x. Review.

PMID:
23620170
5.

Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Irvine E, Williams C.

Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3. Review.

PMID:
23553655
6.
7.

Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.

Wong SF, Mirshahidi H.

Ann Pharmacother. 2011 Jun;45(6):787-97. doi: 10.1345/aph.1P784. Epub 2011 Jun 13. Review.

PMID:
21672900
8.

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.

JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.

PMID:
24715074
9.

Mechanisms of TKI-induced diarrhea in cancer patients.

Bowen JM.

Curr Opin Support Palliat Care. 2013 Jun;7(2):162-7. doi: 10.1097/SPC.0b013e32835ec861. Review.

PMID:
23399616
10.

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.

Teo YL, Ho HK, Chan A.

Cancer Treat Rev. 2013 Apr;39(2):199-206. doi: 10.1016/j.ctrv.2012.09.004. Epub 2012 Oct 23.

PMID:
23099278
11.

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.

Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1099-109. doi: 10.1007/s00280-011-1737-2. Epub 2011 Sep 13. Review.

PMID:
21913033
12.

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.

Dasanu CA, Padmanabhan P, Clark BA 3rd, Do C.

Expert Opin Drug Saf. 2012 May;11(3):445-57. doi: 10.1517/14740338.2012.672971. Epub 2012 Apr 2. Review.

PMID:
22469002
13.

PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.

Slobbe P, Poot AJ, Windhorst AD, van Dongen GA.

Drug Discov Today. 2012 Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2. Review.

PMID:
22766374
14.

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.

Yang B, Papoian T.

J Appl Toxicol. 2012 Dec;32(12):945-51. doi: 10.1002/jat.2813. Epub 2012 Sep 10. Review.

PMID:
22961481
15.

Cardiovascular toxicity of tyrosine kinase inhibitors.

Mouhayar E, Durand JB, Cortes J.

Expert Opin Drug Saf. 2013 Sep;12(5):687-96. doi: 10.1517/14740338.2013.788642. Epub 2013 Apr 8. Review.

PMID:
23560546
16.

Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

Lenihan DJ, Kowey PR.

Oncologist. 2013;18(8):900-8. doi: 10.1634/theoncologist.2012-0466. Epub 2013 Aug 5. Review.

18.

Targeting tyrosine-kinases in ovarian cancer.

Morotti M, Becker CM, Menada MV, Ferrero S.

Expert Opin Investig Drugs. 2013 Oct;22(10):1265-79. doi: 10.1517/13543784.2013.816282. Epub 2013 Jul 2. Review.

PMID:
23815710
19.

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.

Tang C, Gao H, Li X, Liu Y, Li J, Qin H, Wang W, Qu L, An J, Yang S, Liu X.

J Cancer Res Clin Oncol. 2014 Mar;140(3):427-33. doi: 10.1007/s00432-014-1582-x. Epub 2014 Jan 9.

PMID:
24401995
20.

The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.

Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A.

Am J Clin Oncol. 2013 Dec;36(6):620-4. doi: 10.1097/COC.0b013e31825d59db.

PMID:
22892430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk